logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Postoperative Nausea And Vomiting

    Medications for Postoperative Nausea And Vomiting

    FiltersReset Filters
    32 results

    • aponvie

      (APREPITANT)
      Heron Therapeutics, Inc.
      Usage: APONVIE is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. It is not studied for treating already established nausea and vomiting.

    • barhemsys

      (Amisulpride)
      Acacia Pharma Ltd
      Usage: BARHEMSYS® is indicated for adults to prevent and treat postoperative nausea and vomiting (PONV), either alone or in combination with a different class antiemetic, and for patients who have or have not received prior antiemetic prophylaxis.

    • chlorpromazine hydrochloride

      (Chlorpromazine hydrochloride)
      Devatis, Inc.
      Usage: This drug is indicated for treating schizophrenia, controlling nausea and vomiting, relieving pre-surgery anxiety, managing acute intermittent porphyria, adjunctive treatment of tetanus, addressing manic episodes, and treating severe behavioral issues in children, including hyperactivity and conduct disorders.

    • chlorpromazine hydrochloride

      (Chlorpromazine Hydrochloride)
      Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
      Usage: This drug is indicated for managing psychotic disorders, treating schizophrenia, controlling nausea and vomiting, alleviating pre-surgical anxiety, and treating acute intermittent porphyria. It also aids in tetanus treatment, addresses manic-depressive illness, relieves intractable hiccups, and treats severe behavioral issues in children aged 1 to 12.

    • fosaprepitant

      (Fosaprepitant)
      MSN LABORATORIES PRIVATE LIMITED
      Usage: Fosaprepitant for injection is indicated for the prevention of acute and delayed nausea and vomiting in adults and pediatric patients (6 months and older) undergoing highly and moderately emetogenic cancer chemotherapy. It is not studied for treating established nausea and vomiting.

    • granisetron hydrochloride

      (Granisetron Hydrochloride)
      Breckenridge Pharmaceutical, Inc.
      Usage: Granisetron hydrochloride tablets are indicated for preventing nausea and vomiting related to emetogenic cancer therapy (including high-dose cisplatin) and radiation treatments, such as total body irradiation and fractionated abdominal radiation.

    • ondansetron

      (Ondansetron)
      ACTAVIS PHARMA, INC.
      Usage: Ondansetron tablets are indicated for preventing nausea and vomiting from highly and moderately emetogenic cancer chemotherapy, radiotherapy (including total body irradiation and abdominal treatments), and postoperative settings.

    • ondansetron

      (Ondansetron)
      Natco Pharma USA LLC
      Usage: Ondansetron tablets are indicated for preventing nausea and vomiting from highly and moderately emetogenic cancer chemotherapy, specific radiation treatments, and postoperative nausea or vomiting.

    • ondansetron

      (ondansetron hydrochloride)
      Taro Pharmaceuticals U.S.A., Inc.
      Usage: Ondansetron is indicated for preventing nausea and vomiting caused by highly and moderately emetogenic cancer chemotherapy, specific radiotherapy treatments, and postoperative settings.

    • ondansetron

      (Ondansetron Hydrochloride)
      Eugia US LLC
      Usage: Ondansetron Injection is indicated for preventing nausea and vomiting related to emetogenic cancer chemotherapy (for patients aged 6 months and older) and preventing postoperative nausea and vomiting (for patients aged 1 month and older), particularly when avoiding these conditions is critical.